Who are MCS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IDEA-033, TQZ2451, Pf-08052666, Pf-08046045, PF-06939999 in combination with docetaxel, Pf-07248144.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mcs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MCS — Competitive Intelligence Brief

MCS (MCS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule. Area: Cardiovascular.

phase 3 small molecule target molecular target Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

MCS (MCS) — Health Ever Bio-Tech Co., Ltd.. MCS is a small molecule that targets the molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MCS TARGET	MCS	Health Ever Bio-Tech Co., Ltd.	phase 3	small molecule	target molecular target
IDEA-033	IDEA-033	IDEA AG	phase 3	small molecule	target molecular target
TQZ2451	TQZ2451	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	small molecule	target molecular target
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-06939999 in combination with docetaxel	pf-06939999-in-combination-with-docetaxel	Pfizer	marketed	Small molecule inhibitor	Specific protein kinase	Not yet determined
Pf-07248144	pf-07248144	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Not available

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (small molecule class)

Pfizer · 5 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 4 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Cipla BioTec Pvt. Ltd. · 1 drug in this class
ChemRar Research and Development Institute, LLC · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Dilafor AB · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCS — Competitive Intelligence Brief. https://druglandscape.com/ci/mcs. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab